Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC

Cancer Genomics and Proteomics

Volumn 9, Issue 2, 2012, Pages 77-92

  Samakoglu, Selda ^a   Deevi, Dhanvanthri S ^a   Li, Huiling ^a   Wang, Su ^a   Murphy, Mary ^a   Bao, Channa ^a   Bassi, Rajiv ^a   Prewett, Marie ^a   Tonra, James R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

EGFR; Gemcitabine; Methylation; microRNA; NSCLC; Platinum

Indexed keywords

CELL ADHESION MOLECULE; CISPLATIN; DNA METHYLTRANSFERASE 3B; FRAGILE HISTIDINE TRIAD PROTEIN; GEMCITABINE; HSA MIR 29B; NECITUMUMAB; PACLITAXEL; PEMETREXED; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MARKER GENE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DOMAIN;

MUS;

EID: 84863360077     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lustberg MB and Edelman MJ: Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol 8: 38-46, 2007.
2. Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA and Astsaturov I: Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 13: 339-362, 2009.
3. Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson M R, Ellis PA, Pilz K and Reck M: Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small cell lung cancer. Ann Oncol 19: 362-369, 2008. (Pubitemid 351201721)
4. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR and Woytowitz D: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28: 911-917, 2010
5. Hirsh V: Systemic therapies in metastatic non-small cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol 17: 13-23, 2010.
6. Fu M, Wang C, Li Z, Sakamaki T and Pestell RG: Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145: 5439-5447, 2004. (Pubitemid 39564581)
7. Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C and Radinsky R: Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther 8: 1536-1546, 2009.
8. Ragusa M, Majorana A, Statello L, Maugeri M, Salito L, Barbagallo D Barbagallo D, Guglielmino MR, Duro LR, Angelica R, Caltabiano R, Biondi A, Di Vita M, Privitera G, Scalia M, Cappellani A, Vasquez E, Lanzafame S, Basile F, Di Pietro C and Purrello M: Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 9: 3396-3409, 2010.
9. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8: 1207-1216, 2010.
10. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Haney J, Helfrich BA, Kato H, Hirsch FR and Franklin WA: EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 19: 1053-1059, 2008. (Pubitemid 351796329)
11. Dienstmann R and Tabernero J: Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Investig Drugs 11: 1434-1441, 2010.
12. Morgensztern D and Govindan R: Adjuvant chemotherapy for lung cancer: cisplatin doublets only. J Natl Compr Canc Netw 6: 277-284, 2008. (Pubitemid 351488822)
13. Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE and Hicklin DJ: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 12: 2197-2207, 2006.
14. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Brunner T and Vassella E: miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 69: 5553-5559, 2009.
15. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z and Zheng X: Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 582: 1564-1568, 2008.
16. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T and Takahashi T: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756, 2004. (Pubitemid 38697282)
17. Lee YS and Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025-1030, 2007.
18. Chivukula RR and Mendell JT: Circular reasoning: microRNAs and cell-cycle control. Trends Biochem Sci 33: 474-481, 2008.
19. Hornle M, Peters N, Thayaparasingham B, Vorsmann H, Kashkar H and Kulms D: Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene 30: 575-587, 2011.
20. Donnem T, Eklo K, Berg T, Sorbye SW, Lonvik K, Al-Saad S, Andersen S, Stenvold H, Bremnes RM and Busund LT: Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med 9: 6, 2011.
21. Xing J, Stewart DJ, Gu J, Lu C, Spitz MR and Wu X: Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer 98: 1716-1722, 2008. (Pubitemid 351684678)
22. Wang SH, Liu NH, Wang J, Bai H and Mao L: Critical role of deltaDNMT3B4/2 in regulating RASSFlA promoter-specific DNA methylation in non-small cell lung cancer. Chin Med J (Engl) 121: 1712-1721, 2008.
23. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K and Croce CM: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104: 15805-15810, 2007. (Pubitemid 350035380)
24. Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, Palazzo J, McCue PA, Baffa R and Huebner K:. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24: 1625-1633, 2005 (Pubitemid 40396092)
25. Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR and Hicklin DJ: Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res 13: 1540-1551, 2007. (Pubitemid 46450446)
26. Todaro M, Lombardo Y, Francipane MG, Alea MP, Cammareri P, Iovino F, Di Stefano AB, Di Bernardo C, Agrusa A, Condorelli G, Walczak H and Stassi G: Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ 15: 762-772, 2008. (Pubitemid 351405081)
27. Fennell DA: Caspase regulation in non-small cell lung cancer and its potential for therapeutic exploitation. Clin Cancer Res 11: 2097-2105, 2005.
28. Vincenzi B, Zoccoli A, Pantano F, Venditti O and Galluzzo S: Cetuximab: from bench to bedside. Curr Cancer Drug Targets 10: 80-95, 2010.
29. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM and Harris CC: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006. (Pubitemid 43357945)
30. Kitamura Y, Kurosawa G, Tanaka M, Sumitomo M, Muramatsu C, Eguchi K, Akahori Y, Iba Y, Tsuda H, Sugiura M, Hattori Y and Kurosawa Y: Frequent overexpression of CADM1/IGSF4 in lung adenocarcinoma. Biochem Biophys Res Commun 383: 480-484, 2009.
31. Deng WG, Nishizaki M, Fang B, Roth JA and Ji L: Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells. Biochem Biophys Res Commun 355: 993-999, 2007. (Pubitemid 46366925)
32. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, Wang J and Chen L: Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 303: 1, 21-8, 2011.
33. Vallbohmer D, Brabender J, Yang D, Schneider PM, Metzger R, Danenber KD, Holscher AH and Danenberg PV: DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small cell lung cancer: association and prognostic value. Clin Lung Cancer 8: 39-44, 2006. (Pubitemid 44336242)
34. Donninger H, Vos MD and Clark GJ: The RASSFlA tumor suppressor. J Cell Sci 120: 3163-3172, 2007.
35. Lee SJ, Jeon HS, Jang JS, Park SH, Lee GY, Lee BH, Kim CH, Kang YM, Lee WK, Kam S, Park RW, Kim IS, Cho YL, Jung TH and Park JY: DNMT3b polymorphisms and risk of primary lung cancer. Carcinogenesis 26: 403-409, 2005. (Pubitemid 40246562)
36. Beaulieu N, Morin S, Chute IC, Robert MF, Nguyen H and MacLeod AR: An essential role for DNA methyltransferase DNMT3b in cancer cell survival. J Biol Chem 277: 28176-28181, 2002. (Pubitemid 34966771)
37. Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski TM, Maiorino L, Hetzel M, Leschinger M, Visseren-Crul C and Torri V: Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small cell lung cancer. J Clin Oncol 30(2): 172-178, 2012.